Đang chuẩn bị liên kết để tải về tài liệu:
Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: A Delphi consensus study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San Francisco, CA.), effectively managing treatment-related adverse events (AEs) may improve adherence. |

TÀI LIỆU LIÊN QUAN

Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: A Delphi consensus study

Báo cáo y học: "Expert consensus on hospitalization for assessment: a survey in Japan for a new forensic mental health system"

Báo cáo y học: "Helping someone with problem drinking: Mental health first aid guidelines - a Delphi expert consensus study"

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL‑INDIA)